Apogee management looks forward to participating in Bank of America Securities Healthcare Conference this month in Las Vegas. Details below.
Apogee Therapeutics’ Post
More Relevant Posts
-
Our #MarketUpdate report for the week ending February 9th is now available. Highlights include: ➡️US equities continued to rally as the S&P 500 broke the 5,000 threshhold for the first time thanks to strong tech earnings and a better-than-expected January jobs report ➡️Biotech IPOs continue to be active so far in 2024 with two additional companies completing their listings: ➡️Kyverna Therapeutics raised $319.0M to fund their Phase 2 autoimmune cell therapy candidate ➡️Metagenomi raised $93.8M to fund their preclinical gene-editing assets targeting a variety of indications ➡️Last week saw two notable M&A deals announced: ➡️Novo Holdings made headlines with their $16.5B acquisition of Catalent Pharma Solutions, a deal that will give Novo Nordisk additional manufacturing sites to increase the production of their highly popular obesity and diabetes drugs ➡️Novartis announced that they had entered into an agreement to acquire MorphoSys AG for $2.9B, further strengthening their oncology pipeline Read the full update here: https://bit.ly/42zh58M #HealthcareMarket #oncology #gene #autoimmune #IPO #MarketTrends #BBLSA
Back Bay's recap of the public market, financing and M&A activity. Subscribe for the weekly updates: www.bblsa.com
us4.campaign-archive.com
To view or add a comment, sign in
-
Analyst Expectations For Incyte's Future https://ift.tt/n2vS7Xs Latest Ratings for INCY Date Firm Action From To Feb 2022 SVB Leerink Downgrades Market Perform Underperform Feb 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 RBC Capital Upgrades Sector Perform Outperform View More Analyst Ratings for INCY View the Latest Analyst Ratings read more via Benzinga - Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals https://ift.tt/kEDe6jq June 18, 2024 at 11:01AM
Analyst Expectations For Incyte's Future https://ift.tt/n2vS7Xs Latest Ratings for INCY Date Firm Action From To Feb 2022 SVB Leerink Downgrades Market Perform Underperform Feb 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 RBC Capital Upgrades Sector Perform Outperform View More Analyst Ratings for INCY View the Latest Analyst Ratings read more via Benzi...
benzinga.com
To view or add a comment, sign in
-
Providing an alternative Cash Flow Returns On Investments based quantitative & interactive valuation tool.
Have the equivalent of over 100 analysts at your fingertips. Assess companies in minutes using our Cash Flow Returns On Investments based valuation and modeling tools. https://lnkd.in/eJXnSDxy
Incyte Stock: A Potential GARP Superstar (NASDAQ:INCY)
seekingalpha.com
To view or add a comment, sign in
-
Our #MarketUpdate report for the week ending January 26th is now available. Highlights include: ➡️ The Dow and S&P 500 both hit record highs this past week thanks in large part to a faster-than-expected GDP growth of 2.5% for the full 2023 calendar year ➡️ IPOs are officially back – last week saw the first healthcare IPOs of 2024 price as three companies completed their listings, raising an aggregate $1.2B ➡️ Two biotech companies – CG Oncology and ArriVent Biopharma raised $380.0M and $175.0M respectively for their late-stage cancer therapies on the Nasdaq ➡️ BrightSpring Health Services, a healthcare service provider, raised $633.0M on the Nasdaq ➡️ Sanofi made headlines with their $2.2B acquisition of Inhibrx, Inc., adding a potential best-in-class rare disease asset targeting Alpha-1 Antitrypsin Deficiency to their pipeline ➡️ Venture investments saw an uptick in activity, with 13 private financings completed Read the full update here: https://bit.ly/4bb0hsG #HealthcareMarket #oncology #raredisease
Back Bay's recap of the public market, financing and M&A activity. Subscribe for the weekly updates: www.bblsa.com
us4.campaign-archive.com
To view or add a comment, sign in
-
As the saying goes: ‘Patience pays off’. But for Henderson EuroTrust, taking a long-term view with stock selection has paid off handsomely. Find out how now: https://bit.ly/3N0Zxfa #JanusHendersonInvestmentTrusts #JHI #JanusHenderson #InvestmentTrusts #MarketingCommunication For UK investors only. Capital at risk.
Patience pays off with Novo Nordisk
janushenderson.com
To view or add a comment, sign in
-
As the saying goes: ‘Patience pays off’. But for Henderson EuroTrust, taking a long-term view with stock selection has paid off handsomely. Find out how now: https://bit.ly/3N0Zxfa #JanusHendersonInvestmentTrusts #JHI #JanusHenderson #InvestmentTrusts #MarketingCommunication For UK investors only. Capital at risk.
Patience pays off with Novo Nordisk
janushenderson.com
To view or add a comment, sign in
-
As the saying goes: ‘Patience pays off’. But for Henderson EuroTrust, taking a long-term view with stock selection has paid off handsomely. Find out how now: https://bit.ly/3N0Zxfa #JanusHendersonInvestmentTrusts #JHI #JanusHenderson #InvestmentTrusts #MarketingCommunication For UK investors only. Capital at risk.
Patience pays off with Novo Nordisk
janushenderson.com
To view or add a comment, sign in
-
We've definitely seen significant slowdown in IPO and M&A activity over the last few months. The year started off with a decent flurry of activity, but the brakes have definitely been pulled. Here's a decent rundown of the highlights in the space over the last 3 months, worth taking a look. Feels like the upcoming election, BIOSECURE and Inflation Reduction Act are causing a pause in the market here. https://lnkd.in/gnfc9iQF
Fierce Biotech's Quarterly IPO and M&A Roundup: Q2'24
fiercebiotech.com
To view or add a comment, sign in
-
ATTENTION BANKERS, BUSINESS OWNERS, CEO's, CFO's - Alternative Financing for businesses, investors, contractors, developers, business owners.
Read this article and comment below on what your thoughts were on it! Reach out if I can assist with anything! Please note our firm will not be intaking deals from other investment bankers, capital advisory firms, or capital brokers where the third party earns a fee on the funding. #rainstarcapital
Novo Nordisk spends big in France to expand obesity drug capacity
sg.finance.yahoo.com
To view or add a comment, sign in
-
My latest article is out (and open access)! In this analysis of #financialization in US #biopharma, I show how "Our options for saving lives have been overdetermined by finance capitalism." https://lnkd.in/gqacEVN5
‘Financial fallout’ in the US biopharmaceutical industry: Maximizing shareholder value, regulatory capture, and the consequences for patients
sciencedirect.com
To view or add a comment, sign in
13,160 followers